

Special Issue

Cancer Pain: From Basic Research to Drug Discovery and Clinical Studies

Message from the Guest Editors

Cancer pain is one of the worst forms of chronic pain, with opioids being the mainstay of treatment. Unfortunately, most patients quickly develop opioid tolerance, leaving them with few therapeutic alternatives while battling this deadly disease. Thus, there is an urgent need to identify molecular mechanisms driving cancer pain to develop novel analgesic drugs. Most cancer pain occurs when the tumor destroys tissues or presses on nerves. However, cancer cells can also produce substances that make normally innocuous stimuli feel painful. Furthermore, therapeutic interventions can induce pain as an adverse effect, as exemplified by chemotherapy-induced peripheral neuropathy. With this Special Issue, we aim to explore the current state of the cancer pain field, from basic research through to drug discovery and the development to clinical trials. Original research papers, reviews, clinical studies, and meta-analyses of clinical trials are all welcome to contribute.

Guest Editors

Dr. Arpad Szallasi
Prof. Dr. Gabriela Trevisan
Dr. Andreea Dumele

Deadline for manuscript submissions

closed (20 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/170595

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)